-
KIN Dashboard
- Financials
- Filings
-
Holdings
- Transcripts
-
ETFs
- Insider
- Institutional
- Shorts
Kindred Biosciences (KIN)
Company Profile
Quarter (USD) | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 20 | Dec 19 | Dec 18 | Dec 17 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 46.72 mm | 46.72 mm | 46.72 mm | 46.72 mm | 46.72 mm | 46.72 mm |
Cash burn (monthly) | (no burn) | (no burn) | 2.85 mm | 3.31 mm | 881.67 k | 2.42 mm |
Cash used (since last report) | n/a | n/a | 122.55 mm | 142.36 mm | 37.94 mm | 104.10 mm |
Cash remaining | n/a | n/a | -75.83 mm | -95.65 mm | 8.78 mm | -57.38 mm |
Runway (months of cash) | n/a | n/a | -26.6 | -28.9 | 10.0 | -23.7 |
13F holders | Current |
---|---|
Total holders | 7 |
Opened positions | 1 |
Closed positions | 83 |
Increased positions | 1 |
Reduced positions | 2 |
13F shares | Current |
---|---|
Total value | 64.30 mm |
Total shares | 2.62 mm |
Total puts | 0.00 |
Total calls | 109.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Integrated Core Strategies | 2.58 mm | $23.71 mm |
Mint Tower Capital Management B.V. | 13.93 k | $128.00 k |
ELAN Elanco Animal Health | 10.00 k | $93.00 k |
BNP Paribas Arbitrage | 9.41 k | $40.36 mm |
CVA Family Office | 2.50 k | $11.00 k |
Gamco Investors | 11.00 | $0.00 |
Park West Asset Management | 0.00 | $0.00 |
Parallel Advisors | 0.00 | $0.00 |